|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. John L. Lubniewski||Pres, CEO & Director||510,34k||N/D||1964|
|Mr. Shaun D. McMeans||Sr. VP of Fin. & Admin., CFO, Sec. and Treasurer||407,07k||N/D||1962|
|Mr. Byron T. Lawson||Sr. VP & Chief Commercial Officer||349,19k||N/D||1975|
|Ms. Laura Lee Godlewski||VP of Fin. & Principal Accounting Officer||N/D||N/D||1980|
|Dr. Maureen T. Cronin||Sr. VP & Chief Scientific Officer||N/D||N/D||1953|
|Dr. Debra A. Gordon||Sr. VP & Chief Legal Counsel||N/D||N/D||1960|
|Dr. Patrick C. Roche||Sr. VP of R&D||N/D||N/D||1953|
|Laura Beggrow||Pres of Diagnostics||N/D||N/D||N/D|
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
L'ISS Governance QualityScore di HTG Molecular Diagnostics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.